ABMC Signs Master Distribution Agreement with Devor Global

Agreement covers Latin America, including South America

KINDERHOOK, N.Y.--(BUSINESS WIRE)--Feb. 28, 2008--American Bio Medica Corporation (NASDAQ:ABMC) announced today that they have signed a Distribution Agreement with Devor Global, LLP, a privately held company located in the Republic of Panama. Under the agreement, Devor has been granted the exclusive right to distribute ABMC's Rapid STAT(TM) oral fluid drug test and its Rapid TOX Cup(TM) urine based drug test in Latin America, subject to achieving and maintaining annual volume requirements. Devor has also been granted the non-exclusive right to distribute the rest of ABMC's product lines within the territories of Latin America.

ABMC Chief Executive Officer Stan Cipkowski stated, "The principals of Devor are no stranger to ABMC or its products; they have been effectively distributing ABMC's products in Mexico for over 10 years and they are one of our top 10 customers." He added, "We expect they will have the same success in Latin America and are excited about the positive impact this will have on our international sales going forward."

Devor's President Rogelio Oruna stated, "After 10 years as ABMC's top international distributor in Mexico we will use our expertise and knowledge to take this challenge and further develop the markets in Latin America, Spain and Portugal. We plan to make ABMC's drugs of abuse test the leader in these regions as we have done in Mexico."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2006, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

CONTACT: American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer
or
BPC Financial Marketing
John Baldissera, 800-368-1217

SOURCE: American Bio Medica Corporation